Home
Conditions
Hemostatic Disorders

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,072 public trials 579 recruiting studies

Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

NCT06360575

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT05734495

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +17 more
Locations: Beth Israel Deaconness Medical Boston, Massachusetts, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

NCT06566547

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: he First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

NCT04439188

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

A Study of Real Life Treatment for Multiple Myeloma (MM)

NCT04985643

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Altai Regional Clinical Hospital Barnaul, Altayskiy Kray, Russia

Kaluga Regional Clinical Hospital Kaluga, Central Federal District, Russia

Smolensk Clinical Hospital of Russian Railways-Medicine Smolensk, Central Federal District, Russia

City Clinical Hospital No. 1 named after prof. S.I.Sergeev Khabarovsk, Far Eastern Federal District, Russia

View all 24 locations

View Trial Details

Active, Not Recruiting

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Sciences Little Rock, Arkansas, United States

View Trial Details

Active, Not Recruiting

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy Little Rock, Arkansas, United States

View Trial Details

Active, Not Recruiting

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Weill Cornell Medicine - Multiple Myeloma Center New York, United States

View Trial Details

Hemostatic Disorders

Hemostatic Disorders trial results

Related conditions